Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.

@article{Liang2018TreatmentEM,
  title={Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.},
  author={F Liang and Shi-lin Zhang and Qiu Shi Wang and Wen Chao Li},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2018},
  volume={29 5},
  pages={1320-1324}
}
Background The hazard ratio (HR) is used routinely to quantify the treatment effect for time-to-event end points in oncology trials, but its use requires that there be proportional hazards in the treatment arms. Non-proportional hazards are observed frequently in cancer immunotherapy trials due to the long-term survival and delayed clinical effect. Although values of HR are quoted in such trials, they are not valid measures of outcome. Methods Reports of parallel group randomized controlled… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
1 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…